While the therapeutic application of a full length Slit3 may not be appropriate due to its large size that make them difficult to be expressed recombinantly, reducing their stability as well as ease of usage in in vivo studies; the recombinant Slit3 fragments offer a greater benefit for usage in cancer therapy. The gene discussed is SLIT3; the disease is cancer.